Dyslipidemia
A group of conditions in which the levels of fats (lipids) in the blood are abnormal. This can mean high total cholesterol, high triglycerides, low HDL cholesterol or raised LDL cholesterol. Too much cholesterol can build up as plaque in the artery walls.
Also called Dyslipidemias
- Condition
- In this atlas
Overview
Technical summary
MeSH descriptor D050171, a broad heading that MeSH marks as general. It is the parent of the high cholesterol and high triglycerides pages in this atlas. The evidence recorded here is descriptive: a MeSH scope note and two MedlinePlus patient pages.
Burden
No burden claims are published.
Claims and evidence
Context People with high cholesterol or high triglycerides (MedlinePlus patient pages and MeSH)
- Recipient
- Mixed recipients
- Population
- People with abnormal blood fat levels, such as high cholesterol or high triglycerides, as described by MedlinePlus patient pages and MeSH. MedlinePlus says younger people, including children and teens, can also have high cholesterol.
- Care setting
- Not stated; patient information pages and a vocabulary
- Geography
- Not stated; United States federal health agencies
- Life stage
- All ages; the cholesterol page says children and teens can also have high cholesterol
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive page)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
MeSH describes dyslipidemia as abnormal levels of fats (lipids) in the blood, including too much or too little. An abnormal profile may include high total cholesterol, high triglycerides, low HDL cholesterol and raised LDL cholesterol. MedlinePlus says that too much cholesterol in the blood can combine with other substances to form plaque, and that a high level of triglycerides can raise the risk of heart diseases such as coronary artery disease.
Applies to Mixed recipients People with high cholesterol or high triglycerides (MedlinePlus patient pages and MeSH)
- Certainty method
- Not assessed
- Limitations
- MeSH is a vocabulary and its scope note sets no thresholds. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports MeSH scope note for descriptor D050171 (Dyslipidemias)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note for the descriptor.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
32824065c17b49aa6007d7d523ac33514fa5dafd0286380cb76c43c17dfce74d- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports Cholesterol (MedlinePlus health topic)
- Locator
- Summary, What is cholesterol?, para 2
- How it applies
- MedlinePlus on cholesterol and plaque.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
08257871095c35d788ec0fb8751b17ca1c4047c6dcf6e6bf2c88bff852084322- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists summaries on health topic pages, medical test information and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Triglycerides (MedlinePlus health topic)
- Locator
- Summary, What are triglycerides?, para 3
- How it applies
- MedlinePlus on triglycerides and heart disease.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b7cd13120948ff2eeeebcfe6fd34831554fe9cfe21875cc5da03fbe7d3adb110- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists summaries on health topic pages, medical test information and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161, hash only). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Atorvastatin
Applies to Adult People for whom the US label of atorvastatin lists an indication: adults with primary hyperlipidemia
Population, setting and follow-up
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol (LDL cholesterol) indication.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passage read states
The US label of LIPITOR (atorvastatin calcium), in the Viatris Specialty LLC version dated 2024-04-15 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Fenofibrate
Applies to Adult Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules
Population, setting and follow-up
- Adults with severe hypertriglyceridemia, and adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible, as the indications section of the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Pitavastatin
Applies to Adult People for whom the US label of pitavastatin lists an indication: adults with primary hyperlipidemia
Population, setting and follow-up
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol indication.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passage read states
The US label of LIVALO (pitavastatin calcium), in the Kowa Pharmaceuticals America, Inc. version dated 2026-03-31 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Pravastatin
Applies to Adult People for whom the US label of pravastatin lists an indication: adults with primary hyperlipidemia
Population, setting and follow-up
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol indication.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passage read states
The US label of pravastatin sodium tablets (pravastatin sodium), in the Teva Pharmaceuticals USA, Inc. version dated 2024-01-01 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Simvastatin
Applies to Adult People for whom the US label of simvastatin lists an indication: adults with primary hyperlipidemia
Population, setting and follow-up
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol indication.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults, as the passage read states
The US label of ZOCOR (simvastatin), in the Organon LLC version dated 2025-03-28 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 465
Record details
- Record id
cardio:dyslipidemia- Content hash
21fb3dfb777a4105fb16354ec83386a35e8fea2f5223fb3e26bce7f6630a8b33